ATE180261T1 - Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen - Google Patents
Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungenInfo
- Publication number
- ATE180261T1 ATE180261T1 AT91903010T AT91903010T ATE180261T1 AT E180261 T1 ATE180261 T1 AT E180261T1 AT 91903010 T AT91903010 T AT 91903010T AT 91903010 T AT91903010 T AT 91903010T AT E180261 T1 ATE180261 T1 AT E180261T1
- Authority
- AT
- Austria
- Prior art keywords
- proteins
- pharmaceutical
- human lymphocytes
- dna coding
- biological uses
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9000126A FR2656800B1 (fr) | 1990-01-08 | 1990-01-08 | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE180261T1 true ATE180261T1 (de) | 1999-06-15 |
Family
ID=9392569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT91903010T ATE180261T1 (de) | 1990-01-08 | 1991-01-08 | Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US5773578A (de) |
| EP (1) | EP0510079B1 (de) |
| JP (1) | JP2997053B2 (de) |
| AT (1) | ATE180261T1 (de) |
| DE (1) | DE69131249T2 (de) |
| DK (1) | DK0510079T3 (de) |
| ES (1) | ES2134770T3 (de) |
| FR (1) | FR2656800B1 (de) |
| GR (1) | GR3030811T3 (de) |
| IL (1) | IL96907A (de) |
| MX (1) | MX9203379A (de) |
| WO (1) | WO1991010682A1 (de) |
| ZA (1) | ZA91134B (de) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5316920A (en) * | 1992-04-17 | 1994-05-31 | Dana-Faber Cancer Institute, Inc. | Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily |
| JP3700859B2 (ja) | 1994-05-06 | 2005-09-28 | アンスティテュ ギュスタブ ルシ | Ｌａｇ−３タンパク質の可溶性ポリペプチドフラクション；製造方法、治療用製剤、抗イディオタイプ抗体 |
| AU755030B2 (en) * | 1994-05-06 | 2002-11-28 | Institut Gustave Roussy | LAG-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idiotype antibody |
| PT843557E (pt) * | 1995-07-21 | 2003-03-31 | Applied Research Systems | Metodos para detectar indentificar isolar e etiquetar e abordar selectivamente linfocitos th1 por intermedio da proteina lag-3 |
| DE69632967T2 (de) * | 1996-11-29 | 2005-08-11 | Applied Research Systems Ars Holding N.V. | Verfahren zur Verhinderung der Transplantabstoßung bei einer Transplantation und zur Herstellung einer universalen Gentherapie-Wirtszelle unter Anwendung von Lymphocyten-Aktivierungsgen (LAG-3) |
| EP0900841A1 (de) * | 1997-06-18 | 1999-03-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Spleissvarianten von LAG-3 |
| EP0893507A1 (de) | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Verwendung von MHC Klass II Liganden (CD4 und LAG-3) als Adjuvanz für Impfungen und von LAG-3 in der Behandlung von Krebs |
| EP1141288A2 (de) * | 1998-12-18 | 2001-10-10 | Incyte Pharmaceuticals, Inc. | Lymphozytische membranproteine |
| SE0103423D0 (sv) * | 2001-10-12 | 2001-10-12 | Astrazeneca Ab | Polymorphism |
| US20040258678A1 (en) * | 2002-02-22 | 2004-12-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20060240024A1 (en) | 2003-02-28 | 2006-10-26 | The Johns Hopkins University | T cell regulation |
| KR100808925B1 (ko) | 2006-09-29 | 2008-03-03 | 고려대학교 산학협력단 | 돼지 ｌａｇ-3 융합 이뮤노글로블린 |
| EP2044949A1 (de) * | 2007-10-05 | 2009-04-08 | Immutep | Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| RS64268B1 (sr) | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
| GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| EA201691765A1 (ru) | 2014-03-14 | 2016-12-30 | Новартис Аг | Молекулы антител против lag-3 и их применения |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| DK3552615T3 (da) | 2014-07-16 | 2022-02-14 | Transgene | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer |
| ES2833425T3 (es) | 2014-07-16 | 2021-06-15 | Roussy Inst Gustave | Combinación de virus oncolítico con moduladores de punto de control inmunitario |
| JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| US20180340025A1 (en) | 2015-07-29 | 2018-11-29 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
| PE20231958A1 (es) | 2015-07-30 | 2023-12-06 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| CN108367069B (zh) | 2015-12-14 | 2022-08-23 | 宏观基因有限公司 | 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法 |
| BR112018012352A2 (pt) | 2015-12-16 | 2018-12-11 | Merck Sharp & Dohme Corp. | anticorpos anti-lag3 e fragmentos de ligação ao antígeno |
| CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
| US11497781B2 (en) | 2016-03-10 | 2022-11-15 | Cg Oncology, Inc. | Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor |
| BR112019016336A2 (pt) | 2017-02-10 | 2020-03-31 | Regeneron Pharmaceuticals, Inc. | Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto. |
| CN118892540A (zh) | 2017-04-21 | 2024-11-05 | 新罗杰股份有限公司 | 溶瘤痘苗病毒与免疫检查点抑制剂联合疗法 |
| JP7301002B2 (ja) | 2017-05-30 | 2023-06-30 | ブリストル－マイヤーズ スクイブ カンパニー | 抗ｌａｇ－３抗体または抗ｌａｇ－３抗体および抗ｐｄ－１もしくは抗ｐｄ－ｌ１抗体を含む組成物 |
| WO2018222718A1 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Treatment of lag-3 positive tumors |
| WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
| CN119350468A (zh) | 2019-03-29 | 2025-01-24 | 居里研究所 | 具有经修饰的生物活性的白介素-2变体 |
| CA3136568A1 (en) | 2019-05-13 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |
| US20220401539A1 (en) | 2019-10-22 | 2022-12-22 | Institut Curie | Immunotherapy Targeting Tumor Neoantigenic Peptides |
| EP3824954A1 (de) | 2019-11-22 | 2021-05-26 | Centre National de la Recherche Scientifique | Vorrichtung, einrichtung und verfahren zur ministrahl-strahlentherapie |
| WO2021224186A1 (en) | 2020-05-04 | 2021-11-11 | Institut Curie | New pyridine derivatives as radiosensitizers |
| AU2021275489A1 (en) | 2020-05-20 | 2022-12-01 | Centre National De La Recherche Scientifique - Cnrs - | Single domain antibodies and their use in cancer therapies |
| WO2022079270A1 (en) | 2020-10-16 | 2022-04-21 | Université D'aix-Marseille | Anti-gpc4 single domain antibodies |
| EP4232453A1 (de) | 2020-10-20 | 2023-08-30 | Institut Curie | Metallische trans-(n-heterocyclische carben)-amin-platin-komplexe und verwendungen davon zur behandlung von krebs |
| CA3196496A1 (en) | 2020-10-23 | 2022-04-28 | Laurence David TOMS | Lag-3 antagonist therapy for lung cancer |
| EP4247352A1 (de) | 2020-11-18 | 2023-09-27 | Institut Curie | Dimere von biguanidinen und ihre therapeutischen verwendungen |
| EP4277934A1 (de) | 2021-01-14 | 2023-11-22 | Institut Curie | Her2-einzeldomänenantikörpervarianten und cars davon |
| WO2022189618A1 (en) | 2021-03-12 | 2022-09-15 | Institut Curie | Nitrogen-containing heterocycles as radiosensitizers |
| US20240269282A1 (en) | 2021-05-10 | 2024-08-15 | Institut Curie | Methods for the Treatment of Cancer, Inflammatory Diseases and Autoimmune Diseases |
| EP4380682A1 (de) | 2021-08-05 | 2024-06-12 | Institut Curie | Dynamische abtastvorrichtung zur ministrahlerzeugung |
| US20240316061A1 (en) | 2021-09-17 | 2024-09-26 | Institut Curie | Bet inhibitors for treating pab1 deficient cancer |
| WO2023089032A1 (en) | 2021-11-19 | 2023-05-25 | Institut Curie | Methods for the treatment of hrd cancer and brca-associated cancer |
| WO2023099763A1 (en) | 2021-12-03 | 2023-06-08 | Institut Curie | Sirt6 inhibitors for use in treating resistant hrd cancer |
| CN119816320A (zh) | 2022-03-24 | 2025-04-11 | 居里研究所 | 靶向胶质母细胞瘤中肿瘤转座元件衍生的新抗原肽的免疫疗法 |
| EP4499677A1 (de) | 2022-03-31 | 2025-02-05 | Institut Curie | Modifiziertes rela-protein zur induktion der interferonexpression und manipulierte immunzellen mit verbesserter interferonexpression |
| EP4504245A1 (de) | 2022-04-07 | 2025-02-12 | Institut Curie | Durch chimären antigenrezeptor modifizierte myeloidzellen und verwendungen davon zur antikrebstherapie |
| US20250222106A1 (en) | 2022-04-07 | 2025-07-10 | Institut Curie | Myeloid cells modified by chimeric antigen receptor with cd40 and uses thereof for anti-cancer therapy |
| EP4593868A1 (de) | 2022-09-26 | 2025-08-06 | Institut Curie | Myeloidzellen zur expression von il-2 und verwendungen davon zur schnellen antikrebstherapie |
| CN121127264A (zh) | 2023-03-13 | 2025-12-12 | 瑞泽恩制药公司 | 用于在治疗黑素瘤中增强疗效的pd-1抑制剂和lag-3抑制剂组合 |
| EP4683630A1 (de) | 2023-03-21 | 2026-01-28 | Institut Curie | Vps4b-inhibitor zur verwendung in verfahren zur behandlung von hrd-krebs |
| WO2024194402A1 (en) | 2023-03-21 | 2024-09-26 | Institut Curie | Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer |
| WO2024194673A1 (en) | 2023-03-21 | 2024-09-26 | Institut Curie | Methods for the treatment of dedifferentiated liposarcoma |
| EP4695290A1 (de) | 2023-04-13 | 2026-02-18 | Institut Curie | Verfahren zur behandlung von akuter lymphoblastischer t-zell-leukämie |
| WO2025068393A1 (en) | 2023-09-27 | 2025-04-03 | Institut Curie | Methods for the treatment of fibrotic related diseases |
| CN122180519A (zh) | 2023-11-15 | 2026-06-09 | 瑞泽恩制药公司 | 用于增强在治疗肺癌中的功效的pd-1抑制剂和lag-3抑制剂的组合 |
| EP4574165A1 (de) | 2023-12-21 | 2025-06-25 | Egle Therapeutics | Immunozytokine zur krebsbehandlung |
| AU2024405515A1 (en) | 2023-12-21 | 2026-07-02 | Egle Therapeutics | Immunocytokine for cancer treatment |
| AU2025213523A1 (en) | 2024-01-26 | 2026-07-16 | Centre National De La Recherche Scientifique | Lipid degraders to trigger ferroptosis in cancer |
| WO2025202450A1 (en) | 2024-03-28 | 2025-10-02 | Institut Curie | Myeloid cells modified by cytokine chimeric receptor and uses thereof |
| EP4624494A1 (de) | 2024-03-29 | 2025-10-01 | Institut Curie | Her2-einzeldomänenantikörper und verwendungen davon |
| WO2025210252A1 (en) | 2024-04-05 | 2025-10-09 | Institut Curie | Modulators of fam118b protein for use in therapy |
| EP4681780A1 (de) | 2024-07-18 | 2026-01-21 | Egle Therapeutics | Immunozytokine zur krebsbehandlung |
| WO2026017820A1 (en) | 2024-07-18 | 2026-01-22 | Egle Therapeutics | Fusion protein for cancer treatment |
| WO2026035866A1 (en) | 2024-08-07 | 2026-02-12 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor |
| EP4707295A1 (de) | 2024-09-05 | 2026-03-11 | Egle Therapeutics | Interleukin-2-varianten mit modifizierter biologischer aktivität |
| EP4707296A1 (de) | 2024-09-05 | 2026-03-11 | Egle Therapeutics | Interleukin-2-varianten mit modifizierter biologischer aktivität |
| WO2026093520A1 (en) | 2024-10-31 | 2026-05-07 | Institut Curie | Short-csf1-associated extracellular vesicles and uses thereof |
| WO2026154125A2 (en) | 2025-01-17 | 2026-07-23 | Institut Curie | A tumor-specific hla-bound neoantigenic peptide encoded by ewsr1::fli1-induced neogenes |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5109123A (en) * | 1988-06-14 | 1992-04-28 | Dana Farber Cancer Institute | Alteration of ability of soluble CD4 fragments to bind HIV |
| US4994369A (en) * | 1987-12-15 | 1991-02-19 | The Board Of Trustees Of The Leland Stanford Jr. Univ. | T-cell activation related gene |
| US5001230A (en) * | 1988-02-18 | 1991-03-19 | Schering Corporation | T cell activation markers |
-
1990
- 1990-01-08 FR FR9000126A patent/FR2656800B1/fr not_active Expired - Lifetime
-
1991
- 1991-01-08 ES ES91903010T patent/ES2134770T3/es not_active Expired - Lifetime
- 1991-01-08 DE DE69131249T patent/DE69131249T2/de not_active Expired - Fee Related
- 1991-01-08 WO PCT/FR1991/000009 patent/WO1991010682A1/fr not_active Ceased
- 1991-01-08 EP EP91903010A patent/EP0510079B1/de not_active Expired - Lifetime
- 1991-01-08 ZA ZA91134A patent/ZA91134B/xx unknown
- 1991-01-08 DK DK91903010T patent/DK0510079T3/da active
- 1991-01-08 MX MX9203379A patent/MX9203379A/es unknown
- 1991-01-08 JP JP3503112A patent/JP2997053B2/ja not_active Expired - Fee Related
- 1991-01-08 IL IL9690791A patent/IL96907A/en not_active IP Right Cessation
- 1991-01-08 AT AT91903010T patent/ATE180261T1/de not_active IP Right Cessation
-
1995
- 1995-04-04 US US08/416,478 patent/US5773578A/en not_active Expired - Lifetime
- 1995-06-07 US US08/474,988 patent/US5874250A/en not_active Expired - Lifetime
-
1999
- 1999-07-20 GR GR990401899T patent/GR3030811T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69131249D1 (de) | 1999-06-24 |
| JPH05503520A (ja) | 1993-06-10 |
| DK0510079T3 (da) | 1999-11-29 |
| FR2656800A1 (fr) | 1991-07-12 |
| US5773578A (en) | 1998-06-30 |
| IL96907A0 (en) | 1992-03-29 |
| JP2997053B2 (ja) | 2000-01-11 |
| ZA91134B (en) | 1992-08-26 |
| GR3030811T3 (en) | 1999-11-30 |
| MX9203379A (es) | 1992-09-01 |
| WO1991010682A1 (fr) | 1991-07-25 |
| FR2656800B1 (fr) | 1992-05-15 |
| EP0510079A1 (de) | 1992-10-28 |
| DE69131249T2 (de) | 1999-12-30 |
| US5874250A (en) | 1999-02-23 |
| EP0510079B1 (de) | 1999-05-19 |
| ES2134770T3 (es) | 1999-10-16 |
| IL96907A (en) | 1998-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69131249D1 (de) | Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen | |
| ES2142953T3 (es) | Factor de crecimiento y diferenciacion de la familia del tgf-beta. | |
| DE69016426D1 (de) | Biologische klappenprothese. | |
| FI963101A7 (fi) | Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoo n, joissa seerumin interleukiini-6-taso on kohonnut | |
| ITTO950367A0 (it) | Proteine di prrsv ricombinanti, corredi diagnostici e vaccini contenenti tali proteine di prrsv ricombinanti. | |
| AU3310595A (en) | Compositions and methods for identifying biologically active molecules | |
| NO971875L (no) | Cathepsin 02 protease | |
| FR2661187B1 (fr) | Proteine associee a la pancreatite aiguue. moyens pour le diagnostic de la pancreatite aiguue. | |
| NO891805D0 (no) | Flertrinns biologisk renseanlegg. | |
| DE69728897D1 (de) | Saeugetierchemokine | |
| NO883418L (no) | Biologisk dekkskive. | |
| DE69836333D1 (de) | Neisseria lactoferrin-bindendes protein | |
| ATE278781T1 (de) | Tioredioxine h aus zwig und hart-weizen und ähnliche proteine, diese kodierende dna-fragmente und verfahren zu ihrer herstellung | |
| DE68912536D1 (de) | Flüssiges Nahrungsmittel zur Proteinzuführung. | |
| FI902803A7 (fi) | DNA-sekvenssi, joka koodaa a-amylaasi-pullulanaasientsyymiä | |
| PT676413E (pt) | Proteina de ligacao a interferoes alfa/beta, sua preparacao e utilizacao | |
| AU4981093A (en) | Nucleotide sequences coding for cryptosporidium proteins, polypeptides coded by said sequences and kits for the use thereof | |
| NO905496D0 (no) | Biologisk forenelige, stoff-spesifikke reagenser til behandling av fysiologiske vaesker. | |
| FI880412A7 (fi) | Biologista vastetta muuntava aine. | |
| EP0780472A3 (de) | Stress Proteine | |
| DE3880486D1 (de) | Aspirator zur aufnahme von koerperfluessigkeiten. | |
| FI885025A0 (fi) | Koagulationshaemmande protein pp4-x, dess framstaellning och anvaendning. | |
| DE59611293D1 (de) | Protein mit dnase-aktivität | |
| RU95114858A (ru) | Новый пептидный фрагмент, обладающий биологической активностью инсулина | |
| DE69033553D1 (de) | Rekombinante herstellung von laktoperoxidase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |